NED Biosystems Raises $2 Million in Series B Financing Round and Appoints New CEOCompany Announces New Members to Scientific Advisory Board
Including Nobel Laureate Dudley Herschbach, Ph.D.
CAMBRIDGE, Mass., August 1, 2018-- NED Biosystems, a clinical-stage biotech company developing a unique oral oncologic combination treatment that simultaneously attacks 5 cancer-driving processes, today announced it has raised over $2 million toward its Series B round of financing which includes funding from new and existing company investors. Significant investors in this round include Benjamin Griswold IV, Chairman of Brown Advisory, an independent Baltimore-based investment firm.